Q2 FY26 · Ended Jun 30, 2026 · View SEC filing
Net profit grew far faster than sales
Lower deal costs and a lower tax rate explain more of the profit jump than the extra sales do.
SG&A rose 10.4% against 4.8% sales growth, as the company spends more to sell and less on research.
The category worth 38.1% of sales was flat, so growth leaned on hips, extremities, robots and bone cement.
Amortization of acquired intangibles cuts reported profit but not cash, so free cash flow was about double net earnings.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Zimmer Biomet from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
